Companies that understand the regulatory environment in Europe can keep their trials on budget and on schedule.
Elina Smirnova
Advertisement
Associate director of start-up services at Rho
Articles by Elina Smirnova
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade
2
Johnson & Johnson Reaches Agreement with Trump Administration, Continues $55 Billion US-Based Investment Plan
3
Roundup: Pharma’s Funding Surge Ahead of J.P. Morgan 2026
4
Eli Lilly Enters $1.2 Billion Definitive Agreement to Acquire Ventyx Biosciences
5